Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Biological markers and the treatment of Alzheimer's disease
Autore:
Galasko, D;
Indirizzi:
Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA Univ Calif San Diego San Diego CA USA 92103 osci, San Diego, CA 92103 USA
Titolo Testata:
JOURNAL OF MOLECULAR NEUROSCIENCE
fascicolo: 2, volume: 17, anno: 2001,
pagine: 119 - 125
SICI:
0895-8696(200110)17:2<119:BMATTO>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
AMYLOID PRECURSOR PROTEIN; HUMAN CEREBROSPINAL-FLUID; NECROSIS-FACTOR-ALPHA; BIOCHEMICAL MARKER; DIAGNOSTIC MARKER; TAU-PROTEIN; BETA; CSF; DEMENTIA; BETA-AMYLOID((1-42));
Keywords:
biomarker; Alzheimer; amyloid; tau; inflammation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Galasko, D VA Med Ctr, 127,3350 La Jolla Village Dr, San Diego, CA 92161 USA VA Med Ctr 127,3350 La Jolla Village Dr San Diego CA USA 92161
Citazione:
D. Galasko, "Biological markers and the treatment of Alzheimer's disease", J MOL NEURO, 17(2), 2001, pp. 119-125

Abstract

Disease-modifying approaches are being developed to treat Alzheimer's Disease (AD). These are expected to slow the clinical progression of AD or delay the onset of AD. Biological markers, measured in cerebrospinal fluid (CSF) or in the periphery, may be useful adjuncts to clinical assessment methods for AD, especilly when applied to these types of treatment approaches. Markers related to beta-amyloid and tau, components of AD lesions, can be quantified in CSF and show a stable and predictable pattern over time in AD, Biomarkers related to oxidation, such as isoprostanes, and to inflammation may provide information regarding mechanisms leading to neuronal damage. Biomarkers could be used during early clinical testing of drugs that affect key pathogenic steps in AD, such as amyloid production or clearance, to assess drug action and dose-response relationships. In large-scale clinical trials or in clinical practice, biomarkers that are easy to access, such as blood or urine tests, could help in evaluating effects of treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 00:59:20